The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Senolytics: charting a new course or enhancing existing anti tumor therapies? Cellular Oncology Springer Nature Link Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine Targeting the FOXO4 p53 axis by retro inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline Naunyn Schmiedeberg's Archives of Pharmacology Springer Nature Link
Shopping security
Each payment you make on thelockerguy is secured with strict SSL encryption and PCI DSS data protection protocols
product description
Why choose thelockerguy wholesale?
Show More
senolytic peptide foxo4-dri human study The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI